Egg Launches TRIAL360
Virgo Health’s innovation hub, egg, has launched TRIAL360 – white-label technology for a central digital platform enabling maximum clinical trial efficiencies without compromising standards.
TRIAL360 has been developed to encompass all aspects of trial design and execution. It offers quality and convenient training, comprehensive resources, expert support and opportunities for collaborative networking for pharma, investigators and experts all in one place, as well as providing a separate forum for patients to find out more about a clinical trial and access supporting materials after recruitment. It has a proven track record in offering superior clinical trial success – better fulfilling the needs of investigators and patients to help run clinical trials effectively and efficiently.
Compatible across devices with 24/7 access, TRIAL 360 can assist at all stages of a clinical trial. It can be tailored to different phases, is adaptable to individual study designs and can provide real-time detailed analytics to help monitor progress. Being totally customisable it will include only relevant content which can include:
- Protocol development, review and approval
- Investigator site recruitment, training and engagement
- Vendor selection and preparation
- Shared resource libraries
- Patient recruitment and retention
- Data analysis ad boards and read out milestones
Chris Knight, Egg Innovation Director at Virgo Health said, “Increasing the effectiveness of learning and the efficiency of all professional participants, TRIAL360 enables you to build your very own online training platform so that face-to-face time can be better utilised. It offers a new degree of convenience and flexibility through bite-size on-demand sessions ensuring better data accuracy and compliance across study sites globally. It can house personalised learning plans and bespoke training modules – from disease background and study protocols to safety reporting process and data management – which maximise visual and active content to promote knowledge retention.”
For more information please visit www.trial360.co.uk
About Egg
Egg is the healthcare innovation hub powered by Virgo Health. The egg healthcare innovation hub creates products that make a meaningful every day difference to patients, healthcare professionals and the pharmaceutical industry. Egg offers an innovation service to support organisations in solving problems and challenges through a unique process which achieves profound understanding from insight, looking at areas of unmet need through a different lens to create solutions that transform lives. Egg currently has two proprietary white-label products, PRODIGI and TRIAL360.
About Virgo Health
Virgo Health is a global healthcare communications and medical education agency. By applying our Being Human ethos, and recognising what people genuinely feel, believe and do, we develop multi-channel strategies that transform behaviour and reap commercial success.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
